RELAPSED AND REFRACTORY MM PROGRESSING ON 2L
Is SARCLISA + Pd appropriate for your RRMM patients?
Meet Ben – A patient with relapsed and refractory MM with disease progression on 2L treatment
Initial treatment
- Induction therapy was initiated with the bortezomib, thalidomide, dexamethasone (VTd) regimen
- Ben achieved a sCR and received ASCT
Disease progression
- Ben’s disease progressed 3.5 years after ASCT
- Ben received second-line treatment with the lenalidomide, dexamethasone (Rd) regimen and achieved a VGPR
- Two years later, Ben was diagnosed with disease progression after a regular follow-up with his doctor
Additional patient information
- Cytogenetic risk
- Standard
- Bone marrow plasma cells
- 50%
- Hg
- 10 g/dL
- Renal function (CrCl)
- 80 mL/min/1.73 m2
Would Ben be a candidate for treatment with SARCLISA + Pd?
Ben would be suitable for treatment with SARCLISA + Pd1,2
This patient profile does not meet the criteria for use to receive SARCLISA + Pd via the Cancer Drugs Fund. Reimbursement is available at 4L treatment only.*
Percentage of patients receiving SARCLISA + Pd in the ICARIA-MM trial with similar baseline characteristics2
